Xeomin 100 Units

Xeomin 100UI

Xeomin 100UI brings a standard clinic format to professional treatment planning, using botulinum toxin type A for temporary dynamic-line improvement. The result is a product with a defined place in the range rather than a one-size-fits-all option.

What Stands Out

A closer look at Xeomin 100UI shows a product built around practical choices: what it contains, the type of correction it supports and how it differs from adjacent variants.

• Formulation focus: botulinum toxin type A
• Main professional objectives: temporary dynamic-line improvement
• Most relevant treatment areas: upper facial lines
• Presentation details: 100 units

1. Product and Unit Presentation

Xeomin 100UI is positioned as standard 100-unit presentation for focused professional treatment planning. The relationship between its formulation, strength, presentation and professional objective defines this exact product more clearly than its category name alone.

2. Neuromuscular Action

Xeomin 100UI works through botulinum toxin type A, which temporarily limits acetylcholine-mediated signalling between nerves and selected muscles. In professional aesthetic use, this controlled reduction in muscle activity can soften expression-related lines while allowing the treatment plan to be adapted to the area, muscle strength and desired degree of movement.

3. Aesthetic Treatment Objectives

• Softening dynamic expression lines
• Smoother-looking facial lines

4. Common Professional Applications

Xeomin 100UI is commonly associated with:

• Forehead
• Glabellar lines
• Crow’s feet

Final placement and technique for Xeomin 100UI follow the current product instructions and individual assessment.

5. Composition and Vial Specifications

The formulation includes botulinum toxin type A. The sealed label for Xeomin 100UI remains the controlling reference for its exact ingredient statement.

• Product: Xeomin 100UI
• Product type: Botulinum toxin type A product
• Xeomin 100UI: Variant profile: Standard 100-unit presentation for focused professional treatment planning
• Reported strength or volume: 100UI
• Reported formulation: botulinum toxin type A
• Package details: single vial
• Storage profile: refrigerated at 2°C to 8°C

6. Onset and Duration Profile

Reported visible development may begin around 3–4 days, and a duration of approximately 3–4 months is reported. Timing can vary with the treatment area, technique, quantity used and individual response, so the product should be evaluated by the progression and quality of the result rather than by one fixed timetable.

7. Reconstitution, Storage and Handling

The reported package presentation includes single vial. The available product information specifies refrigerated at 2°C to 8°C. The sealed outer box and current instructions remain the controlling handling reference.

8. Choosing the Correct Strength

Xeomin 100UI must remain separate from other strengths in the same toxin family. A 50U, 100U, 200U or 300U presentation changes the total units available in the vial; it does not create an automatic one-to-one treatment plan, because dosing remains product- and practitioner-specific. The exact unit presentation should therefore be selected according to the intended professional use.

9. Frequently Asked Questions

What is Xeomin 100UI?

For Xeomin 100UI, this presentation is a botulinum toxin type A product positioned as standard 100-unit presentation for focused professional treatment planning. Its page is built around the exact formulation and presentation rather than a generic description of the category.

What is the main purpose of Xeomin 100UI?

For Xeomin 100UI, for this formulation, its product profile centres on softening dynamic expression lines and smoother-looking facial lines. The final treatment objective and technique are selected by a qualified professional.

What does Xeomin 100UI contain?

Product information lists botulinum toxin type A.

Which areas are associated with Xeomin 100UI?

The product information associates the named variant with forehead, glabellar lines, and crow’s feet. Suitability and placement depend on the exact product instructions and individual assessment.

How is Xeomin 100UI supplied?

this presentation is described with single vial. Current outer-box information remains the controlling reference for the received market presentation.

What makes this exact version different?

For Xeomin 100UI, the product must remain separate from other strengths in the same toxin family. A 50U, 100U, 200U or 300U presentation changes the total units available in the vial; it does not create an automatic one-to-one treatment plan, because dosing remains product- and practitioner-specific. The exact unit presentation should therefore be selected according to the intended professional use.

10. Professional Use

Manufacturer-Confirmed Details

Merz identifies XEOMIN as a prescription botulinum toxin product used temporarily for moderate-to-severe upper facial lines in adults. The current regional prescribing information must control exact indication and administration. Its potency units are specific to XEOMIN and are not interchangeable with other botulinum toxin preparations.